At a Glance
Direct Comparison
In September 2025, Eli Lilly announced results from ACHIEVE-3, the first head-to-head trial comparing orforglipron directly to oral semaglutide (Rybelsus) in adults with type 2 diabetes.[1]
- Population: 1,698 adults with type 2 diabetes inadequately controlled on metformin
- Duration: 52 weeks
- Design: Open-label, randomized, Phase 3, active-controlled
- Doses compared: Orforglipron 12mg & 36mg vs Oral semaglutide 7mg & 14mg
Primary Outcome: A1C Reduction
Orforglipron demonstrated statistically superior A1C reduction compared to oral semaglutide at both dose levels:
| Medication & Dose | Mean A1C Reduction | Achieving A1C <5.7% | Statistical Significance |
|---|---|---|---|
| Orforglipron 36mg | −2.2% | 37.1% | p < 0.001 |
| Oral Semaglutide 14mg | −1.4% | 12.5% | |
| Orforglipron 12mg | −1.9% | Not reported | p < 0.001 |
| Oral Semaglutide 7mg | −1.1% | Not reported |
Secondary Outcome: Weight Loss
Orforglipron also demonstrated superior weight loss compared to oral semaglutide:
| Medication & Dose | Mean Weight Loss (lbs) | Mean Weight Loss (%) | Relative Difference |
|---|---|---|---|
| Orforglipron 36mg | −19.7 lbs | −9.2% | 73.6% greater |
| Oral Semaglutide 14mg | −11.0 lbs | −5.3% | |
| Orforglipron 12mg | −14.6 lbs | −6.7% | 81.1% greater |
| Oral Semaglutide 7mg | −7.9 lbs | −3.7% |
Orforglipron showed clinically meaningful improvements across key cardiovascular risk factors compared to oral semaglutide:[1]
- Non-HDL cholesterol reduction
- Systolic blood pressure reduction
- Triglyceride reduction
Effectiveness
Beyond the head-to-head trial, it's important to understand how orforglipron compares to injectable semaglutide, which has shown higher efficacy in separate trials.
Direct head-to-head data exists only between orforglipron and oral semaglutide (ACHIEVE-3). Comparisons with injectable semaglutide are based on separate trials with different populations and protocols—indirect comparisons should be interpreted with caution.
Type 2 Diabetes: A1C Reduction
| Drug & Formulation | Mean A1C Reduction | Trial & Population | Comparison Type |
|---|---|---|---|
| Orforglipron 36mg (oral, daily) | −2.2% | ACHIEVE-3: T2D + metformin | DIRECT |
| Oral Semaglutide 14mg (Rybelsus) | −1.4% | ACHIEVE-3: T2D + metformin | DIRECT |
| Injectable Semaglutide 1.0mg (Ozempic) | −1.5% to −2.0% | SUSTAIN trials: Various T2D | INDIRECT |
Interpretation: In the head-to-head ACHIEVE-3 trial, orforglipron 36mg demonstrated superior A1C reduction compared to oral semaglutide 14mg (−2.2% vs −1.4%, p<0.001).[1] Orforglipron's A1C reduction appears comparable to injectable semaglutide 1.0mg from separate trials,[2] though direct comparison is needed for definitive conclusions.
Weight Loss Efficacy
| Drug & Formulation | Mean Weight Loss (%) | ≥10% Weight Loss | Trial Duration | Comparison Type |
|---|---|---|---|---|
| Injectable Semaglutide 2.4mg (Wegovy) | −14.9% | 86.4% | 68 weeks | INDIRECT |
| Orforglipron 36mg (oral) | −11.2% | 50.1% | 72 weeks | INDIRECT |
| Oral Semaglutide 14mg (Rybelsus) | −5% to −8% | ~20-30% | Various | INDIRECT |
Interpretation: Injectable semaglutide 2.4mg (Wegovy) demonstrated the highest weight loss at 14.9%, followed by orforglipron 36mg at 11.2%, and oral semaglutide at 5-8%.[3,4,5] Orforglipron represents a substantial improvement over existing oral GLP-1 options, achieving weight loss closer to injectable formulations.
Tolerability
As GLP-1 receptor agonists, both orforglipron and semaglutide share a similar safety profile with gastrointestinal side effects being most common.
Gastrointestinal Side Effects
| Drug & Dose | Nausea | Vomiting | Discontinuation |
|---|---|---|---|
| Orforglipron 36mg | 33.7% | 24.0% | 6-11% |
| Injectable Semaglutide 2.4mg | 43.9% | 24.5% | 4.3% |
| Oral Semaglutide 14mg | ~20-30% | ~10-15% | ~5-7% |
| Placebo | 8.4-16.1% | 6.3% | 0.7-2.7% |
Interpretation: Gastrointestinal side effects are common across all GLP-1 receptor agonists. Most GI events are mild to moderate (98-99% non-serious), transient, and most common during dose escalation.[6,7] The ACHIEVE-3 head-to-head trial found safety and tolerability were similar between orforglipron and oral semaglutide.[1]
- Contraindicated: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Warnings: Risk of thyroid C-cell tumors (based on rodent studies), pancreatitis, diabetic retinopathy complications, hypoglycemia (when combined with insulin or sulfonylureas)
Real-World Use
Beyond efficacy and safety, practical factors significantly influence medication adherence and patient satisfaction.
Dosing & Administration Comparison
| Factor | Orforglipron | Injectable Semaglutide | Oral Semaglutide |
|---|---|---|---|
| Route | Oral pill | Subcutaneous injection | Oral tablet |
| Frequency | Once daily | Once weekly | Once daily |
| Food requirements | ✓ None – take anytime | ✓ None | ⚠️ Must fast 30 min |
| Timing flexibility | Any time of day | Any time, any day | Morning only, on empty stomach |
| Needles required | No | Yes (weekly) | No |
Unlike oral semaglutide (Rybelsus), orforglipron has no food or liquid intake restrictions, allowing flexible dosing at any time of day.[9] Rybelsus requires patients to:
- Take on an empty stomach first thing in the morning
- Use only 4 oz of plain water (no coffee, tea, or other beverages)
- Wait 30 minutes before eating, drinking, or taking other medications
Access
Cost and insurance coverage are critical factors in medication access and affordability.
Pricing Comparison (2025)
| Drug | List Price (Monthly) | Expected Cost | Availability |
|---|---|---|---|
| Orforglipron | Not yet announced | $149–$299/month self-pay; $50 per monthly fill through the Medicare GLP-1 Bridge (with conditions) | Approved (Foundayo) |
| Injectable Semaglutide (Ozempic/Wegovy) | $997-$1,349 | $0-$150 copay with insurance; $25 with savings card | Approved |
| Oral Semaglutide (Rybelsus) | $997 | $10-$25 with savings card (if eligible) | Approved |
Insurance Coverage Landscape
- Injectable semaglutide (Ozempic): Widely covered by most commercial and Medicare Part D plans with prior authorization
- Oral semaglutide (Rybelsus): Covered by 9 out of 10 commercial plans; Tier 2-3 on Medicare formularies
- Orforglipron: Approved as Foundayo for weight management only; type 2 diabetes needs its own FDA approval
- Injectable semaglutide (Wegovy): Limited coverage; many plans exclude obesity medications
- Oral semaglutide: Approved for weight management as the Wegovy pill (December 22, 2025); coverage varies by plan
- Orforglipron (Foundayo): Coverage varies by plan; people with eligible Part D coverage can get it for weight loss through the Medicare GLP-1 Bridge (outside Part D) for $50 per monthly fill (July 1, 2026 – December 31, 2027), with conditions
Need help with insurance appeals? Honest Care specializes in helping patients navigate insurance coverage and appeals for GLP-1 medications. Start your appeal assessment →
Which to Choose
Choosing between orforglipron and semaglutide depends on individual patient factors, preferences, and clinical circumstances.
Consider Orforglipron If:
- You prefer oral medication without administration restrictions
- You want superior efficacy vs oral semaglutide
- You prefer to avoid injections
- You're comfortable with daily medication
- You want a newly approved option (Foundayo)
- You're looking for lower self-pay cost ($149–$299/month)
Consider Injectable Semaglutide (Ozempic/Wegovy) If:
- You want the highest weight loss efficacy (14.9%)
- You have cardiovascular disease or high risk
- You need medication available now
- You prefer once-weekly dosing
- You value extensive long-term data
- You're comfortable with self-injection
- Your insurance covers it
FAQs
Injectable semaglutide (Wegovy) 2.4mg has demonstrated the highest weight loss at 14.9% over 68 weeks.[5]
Orforglipron 36mg achieved 11.2% weight loss at 72 weeks, representing a substantial improvement over previous oral GLP-1 options.[3]
Oral semaglutide (Rybelsus) showed 5-8% weight loss, making it the least effective option for weight management.[11]
Orforglipron is available now as Foundayo:
- Obesity indication: FDA-approved on April 1, 2026
- Type 2 diabetes: A separate use that needs its own FDA approval
- Medicare: Part D enrollees who meet CMS's criteria pay $50 per monthly fill through the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027)
All three medications share similar side effect profiles as GLP-1 receptor agonists. The most common side effects are gastrointestinal: nausea, vomiting, and diarrhea.[6,7]
The ACHIEVE-3 head-to-head trial found safety and tolerability were similar between orforglipron and oral semaglutide. No formulation has a clear safety advantage—side effect tolerance is highly individual.[1]
Sources
- Eli Lilly and Company. Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial. Press Release, September 17, 2025. Link
- Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol. 2017;5(4):251-260. Link
- Eli Lilly and Company. Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results. Press Release, August 14, 2025. Link
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389(10):877-888. Link
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Link
- Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study. Front Public Health. 2022;10:996179. Link
- Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg. Diabetes Obes Metab. 2022;24(1):94-105. Link
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. Link
- Pratt EC, Kelly MP, Morrow L, et al. Effect of Food Consumption on the Pharmacokinetics of Orforglipron. Clin Pharmacol Drug Dev. 2024;13(3):321-330. Link
- Gelhorn HL, Poon JL, Davies M, et al. Evaluating Preferences for Profiles of GLP-1 Receptor Agonists. Patient Prefer Adherence. 2015;9:1611-1622. Link
- Bucheit JD, Pamulapati LG, Carter N, et al. Oral Semaglutide: A Review of the First Oral GLP-1 Receptor Agonist. Diabetes Technol Ther. 2020;22(1):10-18. Link
- Novo Nordisk. RYBELSUS® (semaglutide) tablets Prescribing Information. 2019. Link
- Eli Lilly and Company. Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial. Press Release, August 28, 2025. Link
- Eli Lilly and Company. Lilly and U.S. government agree to expand access to obesity medicines. Press Release, November 6, 2025. Link
- GoodRx. Is Ozempic Covered by Insurance? 2025. Link
- Novo Nordisk. RYBELSUS® Cost & Coverage Information. NovoCare®, 2025. Link
- ValuePenguin. Costs and Insurance Coverage for Ozempic, Wegovy & Weight Loss Drugs. 2025. Link
Last updated October 6, 2026 · Key facts verified October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.